Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

CSPC Pharmaceutical’s Megalith Subsidiary Enters $1.77 Billion siRNA Collaboration with AstraZeneca for Novel RNAi Therapeutics

Fineline Cube Jul 3, 2026
Company Deals

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Fineline Cube Jul 2, 2026
Company Deals Digital

Insilico Medicine and Takeda Launch $600M Strategic AI Drug Discovery Collaboration – Pharma.AI Platform to Drive Candidate Identification for High-Potential Therapeutic Targets

Fineline Cube Jul 2, 2026
Company Deals

Nona Biosciences and Lonza Forge Strategic Alliance to Develop Best-in-Class Blood-Brain Barrier Penetration Technology for CNS Therapeutics

Fineline Cube Jul 2, 2026
Company Deals

Ipsen to Acquire Memo Therapeutics for €200M Plus Milestones, Gaining Phase II BK Virus Antibody Potravitug for Transplant Nephropathy

Fineline Cube Jul 2, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Shandong Boan Biotechnology Secures NMPA Approval for Phase II Trial of BA1106/BA1104 Combination in NSCLC, China’s First Non-IL-2-Blocking Anti-CD25 Antibody

Fineline Cube Jul 3, 2026
Company Drug

Bio-sincerity Secures NMPA Clinical Trial Approval for BIOS0629-109, Novel XPO1 Inhibitor for Advanced Malignant Tumors

Fineline Cube Jul 3, 2026
Company Deals

Sinopharm Biotec and Ganzhou Government Partner on Medical Testing and Biotech R&D

Fineline Cube Jul 14, 2022

Sinopharm China National Biotec Group Co., Ltd (CNBG) announced a strategic partnership with the government...

Company Deals

Basecare Medical and Haier Biomedical Partner on IVF Cryopreservation Tech

Fineline Cube Jul 14, 2022

China-based IVF specialist Suzhou Basecare Medical Co., Ltd (HKG: 2170) announced a strategic partnership with...

Company Drug

Huadong Medicine’s Biosimilar Victoza (Liraglutide) Accepted for NMPA Review

Fineline Cube Jul 14, 2022

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its market filing for a biosimilar...

Company R&D

CorrectSequence Therapeutics’ tBE Tech Wins USPTO Patent for Gene Editing

Fineline Cube Jul 14, 2022

Shanghai-based gene editing firm CorrectSequence Therapeutics announced it has received a patent from the United...

Company Drug

Zai Lab’s Efgartigimod NDA Accepted by NMPA for Myasthenia Gravis

Fineline Cube Jul 14, 2022

Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) announced that the National Medical Products Administration (NMPA)...

Company Deals

Overland ADCT BioPharma Doses First Patient in Zynlonta’s Phase III LOTIS-5 Study for DLBCL

Fineline Cube Jul 14, 2022

Overland ADCT BioPharma (CY) Ltd, a joint venture between China’s Overland Pharmaceuticals and Switzerland’s ADC...

Company Deals

Triastek Partners with Eli Lilly to Explore 3D Printing for GI Drug Delivery

Fineline Cube Jul 14, 2022

China-based Triastek Inc., a pharmaceutical 3D printing specialist, announced a partnership with US firm Eli...

Company Drug

Zhejiang Medicine’s ARX305 ADC Receives Clinical Trial Approval for CD70-Positive Cancers

Fineline Cube Jul 13, 2022

China-based Zhejiang Medicine Co., Ltd (SHA: 600216) announced that its subsidiary NovoCodex Biopharmaceuticals Ltd has...

Company Deals

GenScript ProBio Partners with ACT Therapeutics on CAR-T Cell Therapy Development

Fineline Cube Jul 13, 2022

GenScript ProBio, a global Contract Development and Manufacturing Organization (CDMO), announced a memorandum of understanding...

Company Drug

Abbisko Therapeutics’ ABSK021 Receives BTD for Giant Cell Tumor Treatment

Fineline Cube Jul 13, 2022

Shanghai-based Abbisko Therapeutics Co., Ltd (HKG: 2256) announced that its Category 1 drug ABSK021 has...

Policy / Regulatory

NMPA Reclassifies Glucosamine Sulfate to OTC, Mandates Label Revisions

Fineline Cube Jul 13, 2022

China’s National Medical Products Administration (NMPA) announced that potassium glucosamine sulfate has been reclassified from...

Policy / Regulatory

China’s JPO Launches VBP Round for Orthopedic Spine Consumables

Fineline Cube Jul 13, 2022

China’s Joint Procurement Office (JPO) announced plans on July 11 to conduct a volume-based procurement...

Company Drug

HutchMed’s Orpathys-Tagrisso Combo Shows Promise in NSCLC at WCLC

Fineline Cube Jul 13, 2022

China-based HutchMed (NASDAQ: HCM, HKG: 0013) announced the publication of an abstract detailing the SAVANNAH...

Company Drug

Junshi Biosciences’ JS203 Bispecific Antibody Receives NMPA Green Light for NHL Study

Fineline Cube Jul 13, 2022

China-based Junshi Biosciences (HKG: 1877, SHA: 688180) announced that the National Medical Products Administration (NMPA)...

Drug

Eli Lilly’s Trulicity + Insulin Combo Meets Goals in China’s AWARD-CHN3 Study

Fineline Cube Jul 13, 2022

Eli Lilly (NYSE: LLY) announced that its Phase III AWARD-CHN3 study of Trulicity (dulaglutide) combined...

Policy / Regulatory

China’s 7th VBP Round Yields 65.5% Drug Price Cuts, Foreign Firms Secure Bids

Fineline Cube Jul 13, 2022

China’s 7th national volume-based procurement (VBP) round concluded with winning bids averaging a 65.5% price...

Company Drug

CDE Grants Priority Review to Ascentage’s Olerembatinib and Roche’s Crovalimab

Fineline Cube Jul 12, 2022

The Center for Drug Evaluation (CDE) has granted priority review status to two drugs: Suzhou...

Company Deals

Athenex Sells China Subsidiaries to TiHe Capital for USD 19 Million

Fineline Cube Jul 12, 2022

US-based Athenex Inc. (Nasdaq: ATNX) announced an agreement to sell all equity interests in its...

Company Deals

Tasly Pharmaceuticals and Mauna Kea Form JV to Commercialize Cellvizio in China

Fineline Cube Jul 12, 2022

China-based Tasly Pharmaceuticals (SHA: 600535) announced a joint venture (JV) with France’s Mauna Kea Technologies...

Company Medical Device

MicroPort MedBot’s Honghu Robot Wins FDA 510(k) Certification for Joint Replacement

Fineline Cube Jul 12, 2022

Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252) announced that its in-house developed orthopedic surgery...

Posts pagination

1 … 674 675 676 … 690

Recent updates

  • Shandong Boan Biotechnology Secures NMPA Approval for Phase II Trial of BA1106/BA1104 Combination in NSCLC, China’s First Non-IL-2-Blocking Anti-CD25 Antibody
  • CSPC Pharmaceutical’s Megalith Subsidiary Enters $1.77 Billion siRNA Collaboration with AstraZeneca for Novel RNAi Therapeutics
  • Bio-sincerity Secures NMPA Clinical Trial Approval for BIOS0629-109, Novel XPO1 Inhibitor for Advanced Malignant Tumors
  • Novartis Secures EU Approval for Itvisma, First Gene Replacement Therapy for Broad SMA Population Including Patients Two Years and Older
  • Ocumension Therapeutics Secures NMPA Approval for OT-502, China’s First Single-Dose Sustained-Release Intraocular Steroid for Postoperative Inflammation
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Shandong Boan Biotechnology Secures NMPA Approval for Phase II Trial of BA1106/BA1104 Combination in NSCLC, China’s First Non-IL-2-Blocking Anti-CD25 Antibody

Company Deals

CSPC Pharmaceutical’s Megalith Subsidiary Enters $1.77 Billion siRNA Collaboration with AstraZeneca for Novel RNAi Therapeutics

Company Drug

Bio-sincerity Secures NMPA Clinical Trial Approval for BIOS0629-109, Novel XPO1 Inhibitor for Advanced Malignant Tumors

Company Drug

Novartis Secures EU Approval for Itvisma, First Gene Replacement Therapy for Broad SMA Population Including Patients Two Years and Older

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.